Indivior PLC

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.

U.S. stock futures were higher this morning, with the Dow futures gaining around 50 points on Tuesday.

Indivior Cuts 2024 Outlook, Joins BP And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Shares of Indivior PLC (LSE:INDV) tanked 31% in a bloody opening session after the drug group sounded the earnings alarm and announced a round of job cuts. In an update, the group said it anticipates adjusted operating profits will be in the range of $285 million to $320 million for the year, down from its previous forecast of $330 million to $380 million.

Indivior tank 31% after drugs group sounds earnings alarm

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). RICHMOND, Va.

Indivior Provides Business Update; Conference Call at 8:00 AM U.S. EDT

Large reductions in the incidence of simulated cardiac arrest caused by potentially lethal doses of fentanyl or carfentanil were observed following a single IN dose of OPVEE compared to a single dose of IN naloxone. Across scenarios of fentanyl or carfentanil overdoses, simultaneous administration of four doses of IN naloxone (4×4 mg) was needed to reduce the incidence of simulated cardiac arrest to values approaching those obtained with a single dose of OPVEE (3mg).

Indivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression and Ca

Double-blind, placebo-controlled study aims to measure safety and efficacy of INDV-2000 over 3 months in participants with moderate to severe Opioid Use Disorder. INDV-2000 is an investigational non-opioid treatment that acts through the orexin pathway, shown to play a key role in the neurobiology of substance use disorder in animals.

Indivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use Disorder

Dublin, June 05, 2024 (GLOBE NEWSWIRE) -- The "Opioid Use Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ResearchAndMarkets.com's offering. The 7 major opioid use disorder markets reached a value of US$ 2 billion in 2023. Looking forward, the 7MM is projected to reach US$ 4.4 billion by 2034, exhibiting a growth rate (CAGR) of 9.16% during 2023-2034. The rising prevalence of opioid addiction, including prescription painkillers and illegal drugs like heroin and fentanyl, is primarily augmenting the opioid use disorder market. Apart from this, the widespread adoption of medication-assisted treatment (MAT) for treating opioid use disorder on account of its several associated benefits, such as improved outcomes, reduced risk of relapse, increased likelihood of long-term recovery, etc., is creating a positive outlook for the market.

Opioid Use Disorder in the 7MM: Epidemiology Insights and Forecast 2024-2034 Featuring Detailed Analysis of Marketed and Late-Stage Pipeline Drugs, Including Subutex and INDV-2000 (Indivior)

RICHMOND, Va., May 23, 2024 /PRNewswire/ -- Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, announced that in anticipation of the expected primary listing of the Company's shares on Nasdaq , members of Indivior's senior leadership team will be hosting an analyst teach-in event today in New York City.

Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance

Indivior PLC (NASDAQ:INDV ) Q1 2024 Earnings Conference Call April 25, 2024 8:00 AM ET Company Participants Jason Thompson - VP, IR Mark Crossley - CEO Christian Heidbreder - Chief Scientific Officer Ryan Preblick - CFO Conference Call Participants James Vane-Tempest - Jefferies Max Herrmann - Stifel Chase Knickerbocker - Craig-Hallum Thibault Boutherin - Morgan Stanley Karl Burns - Northland Capital Markets Max Herrmann - Stifel Operator Good day, and thank you for standing by. Welcome to the Indivior PLC Q1 2024 Financial Results Conference Call.

Indivior PLC (INDV) Q1 2024 Earnings Call Transcript

Indivior PLC (INDV) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.40 per share a year ago.

Indivior PLC (INDV) Q1 Earnings and Revenues Lag Estimates

London-listed pharmaceuticals company Indivior PLC (LSE:INDV) has, as anticipated, confirmed that it will move its primary listing to the US. Shareholders still need to approve the transfer, though this will be seen as a formality given the previously signalled support from major shareholders.

Indivior's US listing confirmation met with fall in shares

SLOUGH, United Kingdom and RICHMOND, Va. , April 25, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024.

Indivior Announces Q1 2024 Financial Results

Indivior (INDV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Indivior (INDV) Surges 5.6%: Is This an Indication of Further Gains?

Indivior PLC (LSE:INDV), the pharma firm developing medicines to treat addiction and mental illnesses, has edged closer to a move to the US after a top-ten shareholder said it would back the move. Last month, the group said it would be considering switching its primary listing on the London Stock Exchange for the Nasdaq, but would consult shareholders beforehand.

Indivior moves a step closer to US listing

Indivior PLC (INDV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Indivior PLC (INDV) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

This head-to-head pharmacodynamic study in healthy volunteers examined the ability of both OPVEE and intranasal naloxone to reverse opioid-induced respiratory depression, which is the shallow and slow breathing associated with an opioid overdose In this model, OPVEE 2.7mg reversed respiratory depression to 95% of pre-opioid baseline within 5 minutes; a similar reversal following a 4 mg dose of intranasal naloxone required 20 minutes RICHMOND, Va. , March 11, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced results from a pharmacodynamic study demonstrating that OPVEE® rapidly reverses opioid-induced respiratory depression, which is the major cause of deaths due to opioid overdose.

Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone

Modine Manufacturing

Interface

Invest in companies like Modine Manufacturing (MOD), Indivior (INDV) and Interface (TILE) that are powered by higher efficiency levels.

3 Must-Buy Efficient Stocks to Strengthen Your Portfolio

RICHMOND, Va. , Feb. 29, 2024 /PRNewswire/ -- Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, today announced that its subsidiary, Indivior Inc., has received final Court approval for its settlement with the Direct Purchaser class, concluding the anti-trust multi-district litigation ("MDL") matter.

Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation

Indivior PLC (NASDAQ:INDV) Q4 2023 Earnings Conference Call February 22, 2024 8:00 AM ET

Indivior PLC (INDV) Q4 2023 Earnings Call Transcript

Indivior PLC (LSE:INDV)'s shares surged 16% in early trading as the drugmaker announced plans to relocate its primary listing from London to New York, seeking to enhance its appeal to US investors as well as aiming for inclusion in major stock indices. The company, known for its opioid use disorder and schizophrenia treatments, revealed this strategic move alongside its full-year results, stating the listing shift could occur in the summer of 2024, pending shareholder approval.

Indivior jumps 16% as market welcomes New York listing plans

UK-listed drugmaker Indivior Plc has begun consulting shareholders on shifting its primary listing to the United States by the middle of this year, it said on Thursday, after reporting a 27% jump in annual profit.

Drugmaker Indivior consults on moving primary listing from London to US

SLOUGH, United Kingdom and RICHMOND, Va. , Feb. 22, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending December 31, 2023.

Indivior Announces Q4 / FY 2023 Financial Results

Teva Pharmaceutical

Indivior PLC (LSE:INDV), a company specialising in addiction treatment, has settled a legal dispute with Actavis, a part of Teva Pharmaceuticals. The disagreement was about Actavis's plan to make a generic version of a drug combining buprenorphine and a naloxone sublingual film.

Indivior settles patent wrangle with Teva subsidiary

With the significant treatment gap, Indivior is well positioned for growth as more patients receive treatment for Opioid Use Disorder. Sublocade, the first FDA-approved buprenorphine LAI for OUD, has seen impressive growth but faces competition from Brixadi, which offers more dosage options, a smaller needle, and a 17% lower price. Indivior shares could rerate 59% higher if analyst estimates materialise.

Indivior: Opioid Use Disorder Market Growth Could Deliver 59% Upside

Reckitt Benckiser Group PLC

Indivior PLC (LSE:INDV, NASDAQ:INDV) has won a case in the High Court against it and former parent Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) after being hit by a lawsuit over the Suboxone branded opioid addiction drug.  In September, Wirral Council filed a claim that Indivior had made misleading or dishonest statements regarding an alleged fraudulent scheme to the market for its Suboxone products in published information relating, violating the Financial Services and Markets Act 2000.

Indivior, Reckitt Benckiser win round one of high court battle over Suboxone anti-opioid claim

Indivior PLC (INDV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

News for Indivior PLC Stock (INDV)